Status summary
- • 6 resolved — Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Trulicity
- • 2 current shortage — Saxenda, Victoza
- • 0 active recalls (past 12 months) — see per-drug detail below
Per-drug status
Wegovy(Novo Nordisk)
resolvedFDA database today: not on the shortage list (checked 2026-10-26)
Resolved: 2025-02-21 · All dose strengths (0.25, 0.5, 1, 1.7, 2.4 mg) removed from FDA shortage list after sustained supply recovery.
Ozempic(Novo Nordisk)
resolvedFDA database today: not on the shortage list (checked 2026-10-26)
Resolved: 2024-12-19 · All dose strengths resolved late 2024. Pharmacy fills generally available.
Zepbound(Eli Lilly)
resolvedFDA database today: not on the shortage list (checked 2026-10-26)
Resolved: 2024-12-19 · Single-dose vial and KwikPen formulations resolved December 2024.
Mounjaro(Eli Lilly)
resolvedFDA database today: not on the shortage list (checked 2026-10-26)
Resolved: 2024-12-19 · All dose strengths (2.5-15 mg) resolved late 2024.
Saxenda(Novo Nordisk)
currentFDA database today: listed with constrained supply (checked 2026-10-26)
Reason: Limited availability. Novo Nordisk has told the FDA that Saxenda will be available until it is discontinued in January 2027 (FDA drug shortage database, posted August 25, 2026).
Rybelsus(Novo Nordisk)
resolvedFDA database today: listed, no supply constraint reported (checked 2026-10-26)
Resolved: 2024-07-15 · No shortage. The Rybelsus brand has been replaced in the US by Ozempic tablets, dispensed since May 4, 2026.
Trulicity(Eli Lilly)
resolvedFDA database today: not on the shortage list (checked 2026-10-26)
Resolved: 2024-08-30 · Lower-demand GLP-1 with stable supply.
Victoza(Novo Nordisk)
currentFDA database today: listed with constrained supply (checked 2026-10-26)
Reason: Limited availability because of shipping delays (FDA drug shortage database, updated August 25, 2026). Victoza is still sold in the US; generic liraglutide in the same doses is listed as available from several manufacturers.
What this means for patients
The 2025 resolution of GLP-1 shortages means brand-name medications (Wegovy, Zepbound, Mounjaro, Ozempic) are generally available at most pharmacies. Compounded GLP-1 production legal basis narrowed post-resolution — patients on compounded products may face increasing pressure to switch to FDA-approved alternatives as the regulatory environment tightens.
For patients who've been managing their treatment around shortages: this is the right time to discuss longer-term planning with your prescriber, especially if you've been bouncing between formulations or pharmacies.
If shortages return
Get FDA shortage-status updates by email below, or opt into price-drop alerts on specific drugs — the same subscriber record covers both.
The GLP1Zoom weekly
GLP-1 price moves & FDA news, in your inbox.
Weekly editorial round-up — partner price changes, new FDA labels, drug-shortage updates, and one independent take. No medical advice; no spam.
Sources
- FDA Drug Shortage Database
- FDA Drug Shortages program page
- Manufacturer-issued supply communications (Novo Nordisk, Eli Lilly)
Status reviewed manually against FDA Drug Shortage Database. Information current as of 2026-09-16. Pharmacy-level availability may differ from FDA-status from distribution timing. Always confirm with your pharmacy before assuming availability. Full disclaimer.